GSK plc or CRISPR Therapeutics AG: Who Invests More in Innovation?

Innovation Investment: A Tale of Two Companies

In the ever-evolving world of biotechnology and pharmaceuticals, investment in research and development (R&D) is crucial for staying ahead. Over the past decade, GSK plc and CRISPR Therapeutics AG have shown contrasting approaches to innovation. From 2014 to 2023, GSK consistently invested significantly more in R&D, with expenditures peaking at approximately $6.2 billion in 2023. This represents a steady increase of around 80% from their 2014 investment.

In contrast, CRISPR Therapeutics AG, a pioneer in gene-editing technology, has shown a remarkable growth trajectory in its R&D spending. Starting from a modest $1.5 million in 2014, their investment surged to nearly $462 million by 2022, marking an impressive increase of over 30,000%. While GSK's investment dwarfs that of CRISPR in absolute terms, the latter's rapid growth underscores its commitment to innovation in a highly competitive field.